Sat, Jul 12, 2014, 7:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

wildbill7711 89 posts  |  Last Activity: Jul 8, 2014 3:37 PM Member since: Jun 16, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • wildbill7711 wildbill7711 Jul 8, 2014 3:37 PM Flag

    Hey it's all about those dam posters...ya know? They're the problem with y'all's portfolio!!! Just caint think strait wit all those mesages goin'on!!!

  • Alzheimer and melanoma data should be huge catalysts for this stock if they show the results we've just seen in herpes and glioma OS

    Sentiment: Buy

  • Reply to

    Buy.......AGen on right road

    by auagboy Jul 8, 2014 11:43 AM
    wildbill7711 wildbill7711 Jul 8, 2014 2:28 PM Flag

    They (novartis) have finished phase2 ... agenus is in phase 3 with melanoma and many other programs in phase 2 are finishing this year.

    Sentiment: Strong Buy

  • wildbill7711 wildbill7711 Jul 8, 2014 2:15 PM Flag

    Google; In early-stage clinical trials at the Hospital of the University of Pennsylvania

    Sentiment: Strong Buy

  • wildbill7711 by wildbill7711 Jul 8, 2014 2:01 PM Flag

    A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation

    The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines – both drugs and biologic agents – that treat serious or life-threatening conditions. This is one of only four Therapies ever given this distinction.

    In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology. AGEN has 23 programs in this same vein as U.P. likely to get a bounce.

    Sentiment: Strong Buy

  • wildbill7711 by wildbill7711 Jul 8, 2014 1:41 PM Flag

    A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation

    The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines – both drugs and biologic agents – that treat serious or life-threatening conditions. This is one of only four Therapies ever given this distinction.

    In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology. AGEN has 23 programs in this same vein as U.P. likely to get a bounce.

    Sentiment: Strong Buy

  • wildbill7711 by wildbill7711 Jul 8, 2014 1:25 PM Flag

    A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation

    The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines – both drugs and biologic agents – that treat serious or life-threatening conditions. This is one of only four Therapies ever given this distinction.

    In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology. AGEN has 23 programs in this same vein as U.P. likely to get a bounce.

    Sentiment: Strong Buy

  • wildbill7711 by wildbill7711 Jul 8, 2014 12:58 PM Flag

    A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation

    The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines – both drugs and biologic agents – that treat serious or life-threatening conditions. This is one of only four Therapies ever given this distinction.

    In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology. AGEN has 23 programs in this same vein as U.P. likely to get a bounce.

  • wildbill7711 by wildbill7711 Jul 8, 2014 12:26 PM Flag

    A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation

    The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines – both drugs and biologic agents – that treat serious or life-threatening conditions. This is one of only four Therapies ever given this distinction.

    In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology. AGEN has 23 programs in this same vein as U.P. likely to get a bounce.

  • wildbill7711 by wildbill7711 Jul 8, 2014 12:21 PM Flag

    A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation

    The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines – both drugs and biologic agents – that treat serious or life-threatening conditions. This is one of only four Therapies ever given this distinction.

    In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology. AGEN has 23 programs in this same vein as U.P. likely to get a bounce.

    Sentiment: Strong Buy

  • Reply to

    Buy.......AGen on right road

    by auagboy Jul 8, 2014 11:43 AM
    wildbill7711 wildbill7711 Jul 8, 2014 12:00 PM Flag

    Great news thanks!

    Sentiment: Buy

  • In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

    "Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD , the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of Translational Research in the Abramson Cancer Center of the University of Pennsylvania.

  • wildbill7711 wildbill7711 Jul 8, 2014 11:30 AM Flag

    You are saying it is bought by the Africans and asians on the street ? I don't think that will be the case. It will be purchased by health care institutions, various governments and relief agencies.

    Sentiment: Buy

  • wildbill7711 wildbill7711 Jul 8, 2014 11:18 AM Flag

    Again, it's 1 program. If proven successful, it will likely end up in a dozen more partnered programs.

    Sentiment: Buy

  • wildbill7711 wildbill7711 Jul 8, 2014 10:54 AM Flag

    Can't say yet, I'm new here. The catalyst will be the proven performance of the technology and the likely approval of all 23 programs more than just how much is the revenue from one program.

    Sentiment: Buy

  • There are a lot of upcoming catalysts for the share price in the next 6 months.

    Sentiment: Buy

  • wildbill7711 wildbill7711 Jul 7, 2014 10:21 AM Flag

    Best of everything to you as well Harry. Congrats on omer!

    Sentiment: Buy

  • Nothing but a bunch of criminals testing the boundary's of an ineffective SRO market and banking system without fear. I had to laugh at the guy that wrote something like if we found a way of bringing the dead back to life we might have gotten an extra 0.20 cents!

    Sentiment: Strong Buy

  • wildbill7711 wildbill7711 Jun 21, 2014 3:46 PM Flag

    Chances? 0 See below or google it.

    Sentiment: Buy

  • wildbill7711 wildbill7711 Jun 21, 2014 3:42 PM Flag

    Off-Label Promotion Is Free Speech
    Jesse C. Vivian, RPh, JD
    Up to one-fifth of all drugs are prescribed off-label and amongst psychiatric drugs, off-label use rises to 31%.[7] In U.S. v Caronia, decided on December 3, 2012, a federal Court of Appeals panel in a 2-1 decision ruled that the promotion of prescription drugs by manufacturer’s agents for off-label purposes is protected “free speech” under the First Amendment to the U.S. Constitution.1 The FDA’s prohibition against such practices was ruled unconstitutional. This decision, if it remains unchanged by any further appeals, will have dramatic implications for the marketing of prescription pharmaceuticals.

    Sentiment: Buy

AEZS
1.25+0.02(+1.63%)Jul 11 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
Immersion Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT